Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jad Chahoud

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|January 3, 2025
The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma: A Meta-AnalysisArfa Mustasam, Kevin Parza, Filip Ionescu, et al.
JAMA Network Open|May 16, 2022
Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell CarcinomaNicholas H Chakiryan, L Robert Gore, Richard R Reich, et al.
Future Oncology (London, England)|October 30, 2025
Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinomaFiras Hatoum, Gabriel Roman Souza, Jeff Johnson, et al.
Cancers|January 26, 2024
Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer StageFilip Ionescu, Jonathan Nguyen, Carlos Moran Segura, et al.
JCO Precision Oncology|July 8, 2024
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor GenomicsWendy Kohlmann, David A Nix, Kristen Pauley, et al.
Lancet (London, England)|June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trialSumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 2, 2024
Pathogenic Roles for RNASET2 in Clear Cell Renal Cell CarcinomaTaylor Peak, Yijun Tian, Aman Patel, et al.
Cancers|August 7, 2021
Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell CarcinomaNicholas H Chakiryan, Gregory J Kimmel, Youngchul Kim, et al.
European Urology|June 19, 2022
Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell CarcinomaAndrew Chang, Nicholas H Chakiryan, Dongliang Du, et al.
European Urology Focus|May 17, 2021
Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell CarcinomaNicholas H Chakiryan, Ali Hajiran, Youngchul Kim, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Journal of the National Comprehensive Cancer Network : JNCCN|January 3, 2025
The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma: A Meta-AnalysisArfa Mustasam, Kevin Parza, Filip Ionescu, et al.
JAMA Network Open|May 16, 2022
Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell CarcinomaNicholas H Chakiryan, L Robert Gore, Richard R Reich, et al.
Future Oncology (London, England)|October 30, 2025
Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinomaFiras Hatoum, Gabriel Roman Souza, Jeff Johnson, et al.
Cancers|January 26, 2024
Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer StageFilip Ionescu, Jonathan Nguyen, Carlos Moran Segura, et al.
JCO Precision Oncology|July 8, 2024
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor GenomicsWendy Kohlmann, David A Nix, Kristen Pauley, et al.
Lancet (London, England)|June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trialSumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 2, 2024
Pathogenic Roles for RNASET2 in Clear Cell Renal Cell CarcinomaTaylor Peak, Yijun Tian, Aman Patel, et al.
Cancers|August 7, 2021
Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell CarcinomaNicholas H Chakiryan, Gregory J Kimmel, Youngchul Kim, et al.
European Urology|June 19, 2022
Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell CarcinomaAndrew Chang, Nicholas H Chakiryan, Dongliang Du, et al.
European Urology Focus|May 17, 2021
Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell CarcinomaNicholas H Chakiryan, Ali Hajiran, Youngchul Kim, et al.
Pageof 10